Glucagon-Like Peptide-1 Receptor Agonists for Patients with Conservatively Managed Nontraumatic Subdural Hematoma
Authors:
- Huanwen ChenHCHuanwen Chen
- Matthew K. McIntyreMMMatthew K. McIntyre
- Jay KakadiyaJKJay Kakadiya
- Pranjal RaiPRPranjal Rai
- Ahmed Y. AzzamAAAhmed Y. Azzam
- Muhammed Amir EssibayiMEMuhammed Amir Essibayi
- Hamza A. SalimHamza A. Salim
- Daniel M. MandelDMDaniel M. Mandel
- Marc BuzzeliMBMarc Buzzeli
- Vivek S. YedavalliVYVivek S. Yedavalli
- Adam A. DmytriwADAdam A. Dmytriw
- Ajay MalhotraAMAjay Malhotra
- 14 August 2026
- journal article
- Published by Wolters Kluwer Health in Neurosurgery
Abstract
BACKGROUND AND OBJECTIVES: Medical management options for nontraumatic subdural hematoma (SDH) remain limited, with only atorvastatin demonstrating benefit in a single phase 2 randomized clinical trial and mixed evidence for dexamethasone. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may benefit SDH outcomes. The objective of this study was to evaluate the association between GLP-1 RA use and rescue surgery rates and mortality in patients with medically managed nontraumatic SDH. METHODS: We conducted a retrospective cohort study using the TriNetX database from 2016 to 2025, including adults with SDH who were managed conservatively without surgical evacuation or middle meningeal artery embolization. Patients prescribed GLP-1 RAs were compared with nonusers. After propensity matching, rescue surgical evacuation, all-cause mortality at 1 year, and GLP-1 RA–associated adverse events were analyzed. RESULTS: A total of 134 901 patients with conservatively managed nontraumatic SDH were identified, of whom 1470 (1.1%) were GLP-1 RA users. After propensity score matching, 2922 patients remained, with 1461 in each group. At 1 year, GLP-1 RA users experienced significantly lower rates of rescue surgery (2.23% vs 3.51%; P = .046), culminating in an overall 38% reduction in relative hazard. All-cause mortality was also significantly lower for GLP-1 RA users at 1 year (16.1% vs 23.7%, P < .001), reflecting a 33% reduction in hazards. GLP-1 RA users did not experience different rates of adverse events, such as pancreatitis, gallbladder disease, or ileus/bowel obstruction (all P > .05). CONCLUSION: Among patients with medically managed nontraumatic SDH, GLP-1 RA use was associated with significantly lower rates of rescue surgery and all-cause mortality without significantly increased risk of common GLP-1 RA–related complications.Keywords
Funding Information
- National Institute of General Medical Sciences (5U54GM104942-08)
This publication has 32 references indexed in Scilit:
- Long-Term Mortality, Cognition, and Quality of Life After Chronic Subdural Hematoma SurgeryJAMA Neurology, 2026
- Beyond Recurrence—Late Effects of Chronic Subdural HematomaJAMA Neurology, 2026
- Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stressFree Radical Biology and Medicine, 2024
- Gradation density hematoma is a predictor of chronic subdural hematoma recurrence associated with inflammation of the outer membraneClinical Neurology and Neurosurgery, 2020
- Long-term excess mortality after chronic subdural hematomaActa Neurochirurgica, 2020
- Safety and Efficacy of Atorvastatin for Chronic Subdural Hematoma in Chinese PatientsJAMA Neurology, 2018
- Local and systemic pro-inflammatory and anti-inflammatory cytokine patterns in patients with chronic subdural hematoma: a prospective studyInflammation Research, 2012
- The surgical management of chronic subdural hematomaNeurosurgical Review, 2011
- Inflammatory Cytokines Locally Elevated in Chronic Subdural HaematomaActa Neurochirurgica, 1998
- Nonsurgical Treatment of Subdural HematomasArchives of Neurology, 1974